All In Biotech

Drug Trial Radar · NCT04802746

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover (Part A) and 2-Arm Parallel Group (Part B) Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants (Part A) and in Study Participants With Mild Asthma (Part B)

Last checked: Nov 20, 2026Latest source record: Nov 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Mar 9, 2021

Primary completion

Nov 22, 2021

Study completion Nov 22, 2021

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Mar 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the pulmonary safety of Staccato alprazolam in healthy study participants and in and study participants with mild asthma

Conditions

  • Healthy Study Participants
  • Participants With Mild Asthma

Interventions

  • AlprazolamDrug

    Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.

  • PlaceboOther

    Study participants will receive Staccato placebo at pre-specified time points in Part A and Part B matching the pre-specified Staccato alprazolam dosing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) to 6 hours postdose on Day 1 in Part ATime frame: From Baseline (predose Day 1) to 6 hours postdose (Day 1)
  2. Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) to 6 hours postdose on Day 4 in Part ATime frame: From Baseline (predose Day 1) to 6 hours postdose (Day 4)
  3. Percentage of study participants with respiratory treatment-emergent adverse events (TEAEs) in Part ATime frame: From Baseline (Day 1) to Safety Follow-up period (up to Day 44)
  4. Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) to 6 hours postdose on Day 1 in Part BTime frame: From Baseline (predose Day 1) to 6 hours postdose (Day 1)
  5. Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) to 6 hours postdose on Day 4 in Part BTime frame: From Baseline (predose Day 1) to 6 hours postdose (Day 4)
  6. Percentage of study participants with respiratory treatment-emergent adverse events (TEAEs) in Part BTime frame: From Baseline (Day 1) to Safety Follow-up period (up to Day 14)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Up0099 101

    North Dartmouth, Massachusetts

  • Up0099 102

    Raleigh, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.